Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Discov. 2018 Apr;8(4):389-391. doi: 10.1158/2159-8290.CD-18-0125.
Colorectal cancer with mutation can be effectively treated with combination approaches involving inhibition of BRAF, MEK, and EGFR proteins. However, activation of the MAPK pathway, often due to emergence of previously undetected molecular alterations, ultimately leads to adaptive therapeutic resistance. Novel combination strategies combining inhibition of BRAF, ERK, and EGFR can be used to prevent MAPK pathway-driven resistance and warrant further investigation. .
存在 突变的结直肠癌可以通过包含 BRAF、MEK 和 EGFR 蛋白抑制的联合治疗方法进行有效治疗。然而，MAPK 通路的激活通常是由于先前未检测到的分子改变的出现，最终导致适应性治疗抵抗。联合抑制 BRAF、ERK 和 EGFR 的新的联合策略可用于预防 MAPK 通路驱动的耐药性，并值得进一步研究。
